The genome is the total DNA content present in a cell of an individual organism. Genomics is a sub-segment of genetics that deals with the study of the sequencing and analysis of an organism’s genome. Clinical genomics specifically deals with the study of an organism’s genetic make-up for medical purposes such as prognosis or diagnosis of a disease, determination of pre-existing causes of a probable disease, and customization of treatment regime as per the patient’s need. Growth of molecular biology has transformed the diagnosis and treatment of diseases. Modern test methods, based on the detection of DNA and RNA, offer several advantages over traditional methods for the detection of diseases. The new procedures can detect viruses, bacteria, and genetic variations faster and much more accurately.
Continuous innovation in clinical genomics has led to personalized health care for better treatment plans for patients. Genetic sequencing provides various types of technologies for diagnosis of genetic disorders, some of the prominent technology are RT-PCR, microarray sequencing, and next generation sequencing. Availability of a wide range of technologies for diagnosis of disease presents several choices depending upon cost of test, capability, and other parameters. This is likely to drive the global clinical genomics market during the forecast period. Comparative genomic hybridization (CGH) or chromosomal microarray analysis (CMA) is a method of detecting copy number variations. It is considered to be an emerging technology that finds usage in the detection of both chromosomal disorders and solid tumors. Array comparative genomic hybridization (aCGH) is an advanced CGH technique that is emerging as a preferred choice over other traditional techniques due to advancements in terms of workflow and cost effectiveness. The technology is expected to replace existing traditional banding techniques and positively impact the growth of the clinical genomics market. According to the World Health Organization (WHO), cancer accounts for 8.3 million deaths each year, with 70% new cancer cases expected to be reported in the next 20 years. Each cancer type requires unique treatment. Hence, rise in prevalence of cancer and the need of personalized medicine are expected to drive demand for clinical genomics during the forecast period. This is likely to provide significant opportunities for players in the clinical genomics market, as it is still in a nascent stage.
The global clinical genomics market can be segmented based on product type, application, end-user, and region. In terms of product type, the market can be divided into instruments, consumables & reagents, and services. Based on application, the global clinical genomics market can be classified into diagnostics, newborn screening, genetics, carrier screening, and prenatal screening. In terms of end-user, the market can be categorized into hospitals, clinics, and diagnostic laboratories. Hospitals and diagnostic laboratories are anticipated to be the major segments of the clinical genomics market during the forecast period.
In terms of region, the global clinical genomics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to be the dominant markets for clinical genomics due to high health care expenditure, and high awareness and acceptance of novel diagnostic methods. Changing demographics in emerging economies such as China, India, Brazil, and South Africa are expected to present high growth opportunities in the clinical genomics market. Public and private health care expenditure in these countries is expected to increase, which in turn is likely to drive the focus of manufacturers to these markets. Improvement in health care infrastructure and government reimbursement programs in the developed as well as developing countries are likely to present opportunities in the global clinical genomics market in the near future.
Key players in the global clinical genomics market include Abbott Laboratories, PerkinElmer, Inc., Beckman Coulter, Inc. (Danaher Corporation), Myriad Genetics, Inc., Illumina, Inc., Astute Medical, Inc., and Thermo Fisher Scientific, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.